„Lancet” wycofał publikację o hydroksychlorochinie. Publikujemy wyjaśnienia autorów
Autor: Krystian Lurka
Data: 05.06.2020
Źródło: KZ/KL
Mandeep R. Mehra, Frank Ruschitzka i Amit N. Patel – autorzy artykułu dotyczącego hydroksychlorochiny i jej zastosowania w leczeniu COVID-19 – wycofali swoją pracę opublikowaną w „The Lancet”. Dlaczego? Pojawiły się wątpliwości dotyczące spójności danych dostarczonych przez firmę Surgisphere Corporation. Po tym jak eksperci nie byli w stanie ich sprawdzić i potwierdzić wyników badań, zdecydowano o odwołaniu artykułu. „Menedżer Zdrowia” udostępnia wyjaśnienia autorów w oryginale.
Decyzja autorów zapadła po tym, jak najważniejsze czasopisma medyczne zgłosiły zastrzeżenia co do rzetelności przeprowadzanych badań. Komitetu ds. Etyki Publikacji (COPE) i Międzynarodowe Komitetu Redaktorów Czasopism Medycznych (ICMJE) stwierdziły, że potrzebny jest natychmiastowy audyt działalności badawczej Surgisphere Corporation.
Co napisali autorzy?
Wyjaśnienia Mandeepa R. Mehra, Franka Ruschitzka i Amita N. Pate´a:
– After publication of our Lancet Article1, several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication. We launched an independent thirdparty peer review of Surgisphere with the consent of Sapan Desai to evaluate the origination of the database elements, to confirm the completeness of the database, and to replicate the analyses presented in the paper. Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. We always aspire to perform our research in accordance with the highest ethical and professional guidelines. We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted. We all entered this collaboration to contribute in good faith and at a time of great need during the COVID-19 pandemic. We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused. MRM reports personal fees from Abbott, Medtronic, Janssen, Roivant, Triple Gene, Mesoblast, Baim Institute for Clinical Research, Portola, Bayer, NupulseCV, FineHeart, and Leviticus. FR has been paid for time spent as a committee member for clinical trials, advisory boards, other forms of consulting, and lectures or presentations; these payments were made directly to the University of Zurich and no personal payments were received in relation to these trials or other activities since 2018. Before 2018 FR reports grants and personal fees from SJM/Abbott, grants and personal fees from Servier, personal fees from Zoll, personal fees from Astra Zeneca, personal fees from Sanofi, grants and personal fees from Novartis, personal fees from Amgen, personal fees from BMS, personal fees from Pfizer, personal fees from Fresenius, personal fees from Vifor, personal fees from Roche, grants and personal fees from Bayer, personal fees from Cardiorentis, personal fees from Boehringer Ingelheim, other from Heartware, and grants from Mars. ANP declares no competing interests.
1Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; published online May 22. https://doi.org/10.1016/S0140-6736(20)31180-6.
Jeśli chcesz ściągnąć oświadczenie autorów w pdf, kliknij w: „Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19 a multinational registry analysis”.
Przeczytaj także: „Prof. Tomasiewicz: Pacjentów z COVID-19 musimy leczyć już dzisiaj”.
Zachęcamy do polubienia profilu „Menedżera Zdrowia” na Facebooku: www.facebook.com/MenedzerZdrowia i obserwowania kont na Twitterze i LinkedInie: www.twitter.com/MenedzerZdrowia i www.linkedin.com/MenedzerZdrowia.
Co napisali autorzy?
Wyjaśnienia Mandeepa R. Mehra, Franka Ruschitzka i Amita N. Pate´a:
– After publication of our Lancet Article1, several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication. We launched an independent thirdparty peer review of Surgisphere with the consent of Sapan Desai to evaluate the origination of the database elements, to confirm the completeness of the database, and to replicate the analyses presented in the paper. Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process. We always aspire to perform our research in accordance with the highest ethical and professional guidelines. We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources. Due to this unfortunate development, the authors request that the paper be retracted. We all entered this collaboration to contribute in good faith and at a time of great need during the COVID-19 pandemic. We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused. MRM reports personal fees from Abbott, Medtronic, Janssen, Roivant, Triple Gene, Mesoblast, Baim Institute for Clinical Research, Portola, Bayer, NupulseCV, FineHeart, and Leviticus. FR has been paid for time spent as a committee member for clinical trials, advisory boards, other forms of consulting, and lectures or presentations; these payments were made directly to the University of Zurich and no personal payments were received in relation to these trials or other activities since 2018. Before 2018 FR reports grants and personal fees from SJM/Abbott, grants and personal fees from Servier, personal fees from Zoll, personal fees from Astra Zeneca, personal fees from Sanofi, grants and personal fees from Novartis, personal fees from Amgen, personal fees from BMS, personal fees from Pfizer, personal fees from Fresenius, personal fees from Vifor, personal fees from Roche, grants and personal fees from Bayer, personal fees from Cardiorentis, personal fees from Boehringer Ingelheim, other from Heartware, and grants from Mars. ANP declares no competing interests.
1Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020; published online May 22. https://doi.org/10.1016/S0140-6736(20)31180-6.
Jeśli chcesz ściągnąć oświadczenie autorów w pdf, kliknij w: „Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19 a multinational registry analysis”.
Przeczytaj także: „Prof. Tomasiewicz: Pacjentów z COVID-19 musimy leczyć już dzisiaj”.
Zachęcamy do polubienia profilu „Menedżera Zdrowia” na Facebooku: www.facebook.com/MenedzerZdrowia i obserwowania kont na Twitterze i LinkedInie: www.twitter.com/MenedzerZdrowia i www.linkedin.com/MenedzerZdrowia.
